Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

MCTA vs ACMR vs ICHR vs CANG vs MKSI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
MCTA
Charming Medical Limited Class A Ordinary Shares

Medical - Care Facilities

HealthcareNASDAQ • HK
Market Cap$445M
5Y Perf.+33.2%
ACMR
ACM Research, Inc.

Semiconductors

TechnologyNASDAQ • US
Market Cap$4.17B
5Y Perf.+216.1%
ICHR
Ichor Holdings, Ltd.

Semiconductors

TechnologyNASDAQ • US
Market Cap$2.55B
5Y Perf.+222.1%
CANG
Cango Inc.

Auto - Dealerships

Consumer CyclicalNYSE • CN
Market Cap$272M
5Y Perf.-75.7%
MKSI
MKS Inc.

Hardware, Equipment & Parts

TechnologyNASDAQ • US
Market Cap$20.99B
5Y Perf.+195.1%

MCTA vs ACMR vs ICHR vs CANG vs MKSI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
MCTA logoMCTA
ACMR logoACMR
ICHR logoICHR
CANG logoCANG
MKSI logoMKSI
IndustryMedical - Care FacilitiesSemiconductorsSemiconductorsAuto - DealershipsHardware, Equipment & Parts
Market Cap$445M$4.17B$2.55B$272M$20.99B
Revenue (TTM)$6M$960M$959M$3.46B$4.07B
Net Income (TTM)$1M$91M$-51M$-178M$327M
Gross Margin67.2%44.2%11.3%13.6%45.2%
Operating Margin22.3%12.5%-3.8%7.3%14.8%
Forward P/E414.5x32.4x53.2x6.1x27.1x
Total Debt$1M$303M$186M$170M$4.69B
Cash & Equiv.$817K$766M$98M$1.29B$675M

MCTA vs ACMR vs ICHR vs CANG vs MKSILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

MCTA
ACMR
ICHR
CANG
MKSI
StockMay 20May 26Return
ACM Research, Inc. (ACMR)100316.1+216.1%
Ichor Holdings, Ltd. (ICHR)100322.1+222.1%
Cango Inc. (CANG)10024.3-75.7%
MKS Inc. (MKSI)100295.1+195.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: MCTA vs ACMR vs ICHR vs CANG vs MKSI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MCTA leads in 3 of 7 categories (5-stock set), making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Cango Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. ACMR and MKSI also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
MCTA
Charming Medical Limited Class A Ordinary Shares
The Quality Compounder

MCTA carries the broadest edge in this set and is the clearest fit for quality and momentum.

  • 19.3% margin vs ICHR's -5.3%
  • +319.3% vs CANG's -73.2%
  • 23.4% ROA vs ICHR's -5.2%, ROIC 265.0% vs -3.9%
Best for: quality and momentum
ACMR
ACM Research, Inc.
The Growth Play

ACMR ranks third and is worth considering specifically for growth exposure and long-term compounding.

  • Rev growth 15.2%, EPS growth -10.5%, 3Y rev CAGR 32.3%
  • 32.7% 10Y total return vs MKSI's 7.8%
  • 15.2% revenue growth vs CANG's -52.7%
Best for: growth exposure and long-term compounding
ICHR
Ichor Holdings, Ltd.
The Technology Pick

Among these 5 stocks, ICHR doesn't own a clear edge in any measured category.

Best for: technology exposure
CANG
Cango Inc.
The Defensive Pick

CANG is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 2.49, Low D/E 4.1%, current ratio 1.88x
  • Lower P/E (6.1x vs 53.2x)
  • Beta 2.49 vs ICHR's 3.78, lower leverage
Best for: sleep-well-at-night
MKSI
MKS Inc.
The Income Pick

MKSI is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 0 yrs, beta 2.56, yield 0.3%
  • Beta 2.56, yield 0.3%, current ratio 2.71x
  • 0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend)
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthACMR logoACMR15.2% revenue growth vs CANG's -52.7%
ValueCANG logoCANGLower P/E (6.1x vs 53.2x)
Quality / MarginsMCTA logoMCTA19.3% margin vs ICHR's -5.3%
Stability / SafetyCANG logoCANGBeta 2.49 vs ICHR's 3.78, lower leverage
DividendsMKSI logoMKSI0.3% yield, vs ACMR's 0.2%, (3 stocks pay no dividend)
Momentum (1Y)MCTA logoMCTA+319.3% vs CANG's -73.2%
Efficiency (ROA)MCTA logoMCTA23.4% ROA vs ICHR's -5.2%, ROIC 265.0% vs -3.9%

MCTA vs ACMR vs ICHR vs CANG vs MKSI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

MCTACharming Medical Limited Class A Ordinary Shares

Segment breakdown not available.

ACMRACM Research, Inc.
FY 2025
Total Single Wafer and Semi-Critical Cleaning Equipment
69.5%$626M
ECP Front End And Packaging Furnace And Other Technologies
22.1%$200M
Advanced Packaging (exclude ECP), Services & Spares
8.4%$76M
ICHRIchor Holdings, Ltd.

Segment breakdown not available.

CANGCango Inc.
FY 2024
After-market Service Facilitation Service Income
62.9%$41M
Loan Facilitation Income And Other Related Income
24.1%$16M
Automobile trading income
9.6%$6M
Service, Other
3.4%$2M
MKSIMKS Inc.
FY 2025
Product
87.4%$3.4B
Service
12.6%$495M

MCTA vs ACMR vs ICHR vs CANG vs MKSI — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCTALAGGINGMKSI

Income & Cash Flow (Last 12 Months)

MCTA leads this category, winning 3 of 6 comparable metrics.

MKSI is the larger business by revenue, generating $4.1B annually — 654.5x MCTA's $6M. MCTA is the more profitable business, keeping 19.3% of every revenue dollar as net income compared to ICHR's -5.3%. On growth, CANG holds the edge at +58.3% YoY revenue growth, suggesting stronger near-term business momentum.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.MKSI logoMKSIMKS Inc.
RevenueTrailing 12 months$6M$960M$959M$3.5B$4.1B
EBITDAEarnings before interest/tax$139M-$11M$333M$945M
Net IncomeAfter-tax profit$91M-$51M-$178M$327M
Free Cash FlowCash after capex-$108M-$17M$0$401M
Gross MarginGross profit ÷ Revenue+67.2%+44.2%+11.3%+13.6%+45.2%
Operating MarginEBIT ÷ Revenue+22.3%+12.5%-3.8%+7.3%+14.8%
Net MarginNet income ÷ Revenue+19.3%+9.5%-5.3%-5.2%+8.0%
FCF MarginFCF ÷ Revenue+2.2%-11.3%-1.7%-154.0%+9.8%
Rev. Growth (YoY)Latest quarter vs prior year+34.2%+4.7%+58.3%+15.2%
EPS Growth (YoY)Latest quarter vs prior year-20.0%+46.2%+3.6%+53.2%
MCTA leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

CANG leads this category, winning 3 of 6 comparable metrics.

At 6.1x trailing earnings, CANG trades at a 99% valuation discount to MCTA's 414.5x P/E. On an enterprise value basis, CANG's 3.9x EV/EBITDA is more attractive than MCTA's 269.8x.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.MKSI logoMKSIMKS Inc.
Market CapShares × price$445M$4.2B$2.5B$272M$21.0B
Enterprise ValueMkt cap + debt − cash$446M$3.7B$2.6B$107M$25.0B
Trailing P/EPrice ÷ TTM EPS414.55x45.98x-47.58x6.14x71.33x
Forward P/EPrice ÷ next-FY EPS est.32.43x53.16x27.14x
PEG RatioP/E ÷ EPS growth rate1.30x
EV / EBITDAEnterprise value multiple269.80x29.49x3.90x27.51x
Price / SalesMarket cap ÷ Revenue71.60x4.63x2.69x2.29x5.34x
Price / BookPrice ÷ Book value/share9999.00x2.20x3.78x0.45x7.76x
Price / FCFMarket cap ÷ FCF3219.65x42.22x
CANG leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

MCTA leads this category, winning 7 of 9 comparable metrics.

MCTA delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-8 for ICHR. CANG carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to MCTA's 23.57x. On the Piotroski fundamental quality scale (0–9), MCTA scores 6/9 vs ACMR's 2/9, reflecting solid financial health.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.MKSI logoMKSIMKS Inc.
ROE (TTM)Return on equity+24.4%+5.1%-7.5%-4.1%+12.2%
ROA (TTM)Return on assets+23.4%+3.4%-5.2%-2.3%+3.7%
ROICReturn on invested capital+2.6%+7.0%-3.9%+4.6%+6.5%
ROCEReturn on capital employed+3.4%+6.6%-4.7%+4.5%+7.2%
Piotroski ScoreFundamental quality 0–962346
Debt / EquityFinancial leverage23.57x0.16x0.28x0.04x1.73x
Net DebtTotal debt minus cash$343,868-$463M$87M-$1.1B$4.0B
Cash & Equiv.Liquid assets$816,771$766M$98M$1.3B$675M
Total DebtShort + long-term debt$1M$303M$186M$170M$4.7B
Interest CoverageEBIT ÷ Interest expense66.54x20.41x-5.97x-1.87x2.84x
MCTA leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

ACMR leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in MCTA five years ago would be worth $41,929 today (with dividends reinvested), compared to $9,668 for CANG. Over the past 12 months, MCTA leads with a +319.3% total return vs CANG's -73.2%. The 3-year compound annual growth rate (CAGR) favors ACMR at 90.2% vs CANG's 1.3% — a key indicator of consistent wealth creation.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.MKSI logoMKSIMKS Inc.
YTD ReturnYear-to-date-0.0%+40.4%+259.0%-58.7%+85.3%
1-Year ReturnPast 12 months+319.3%+155.8%+298.0%-73.2%+244.5%
3-Year ReturnCumulative with dividends+319.3%+588.4%+168.5%+4.0%+283.4%
5-Year ReturnCumulative with dividends+319.3%+194.1%+53.9%-3.3%+90.5%
10-Year ReturnCumulative with dividends+319.3%+3268.4%+650.1%-44.2%+777.0%
CAGR (3Y)Annualised 3-year return+61.3%+90.2%+39.0%+1.3%+56.5%
ACMR leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CANG and MKSI each lead in 1 of 2 comparable metrics.

CANG is the less volatile stock with a 2.49 beta — it tends to amplify market swings less than ICHR's 3.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MKSI currently trades 95.4% from its 52-week high vs CANG's 20.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.MKSI logoMKSIMKS Inc.
Beta (5Y)Sensitivity to S&P 5003.17x3.78x2.49x2.56x
52-Week HighHighest price in past year$31.70$71.65$78.00$2.88$326.83
52-Week LowLowest price in past year$4.30$21.87$13.12$0.33$80.22
% of 52W HighCurrent price vs 52-week peak+92.6%+87.9%+93.9%+20.2%+95.4%
RSI (14)Momentum oscillator 0–10078.572.670.167.074.1
Avg Volume (50D)Average daily shares traded01.1M790K1.4M1.2M
Evenly matched — CANG and MKSI each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CANG and MKSI each lead in 1 of 2 comparable metrics.

Analyst consensus: ACMR as "Buy", ICHR as "Buy", CANG as "Buy", MKSI as "Buy". Consensus price targets imply 414.9% upside for CANG (target: $3) vs -25.5% for ICHR (target: $55). For income investors, MKSI offers the higher dividend yield at 0.28% vs ACMR's 0.18%.

MetricMCTA logoMCTACharming Medical …ACMR logoACMRACM Research, Inc.ICHR logoICHRIchor Holdings, L…CANG logoCANGCango Inc.MKSI logoMKSIMKS Inc.
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$75.00$54.60$3.00$294.25
# AnalystsCovering analysts1014229
Dividend YieldAnnual dividend ÷ price+0.2%+0.3%
Dividend StreakConsecutive years of raises3150
Dividend / ShareAnnual DPS$0.11$0.87
Buyback YieldShare repurchases ÷ mkt cap0.0%+0.2%0.0%+4.9%+0.2%
Evenly matched — CANG and MKSI each lead in 1 of 2 comparable metrics.
Key Takeaway

MCTA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CANG leads in 1 (Valuation Metrics). 2 tied.

Best OverallCharming Medical Limited Cl… (MCTA)Leads 2 of 6 categories
Loading custom metrics...

MCTA vs ACMR vs ICHR vs CANG vs MKSI: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is MCTA or ACMR or ICHR or CANG or MKSI a better buy right now?

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus -52. 7% for Cango Inc. (CANG). Cango Inc. (CANG) offers the better valuation at 6. 1x trailing P/E, making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — MCTA or ACMR or ICHR or CANG or MKSI?

On trailing P/E, Cango Inc.

(CANG) is the cheapest at 6. 1x versus Charming Medical Limited Class A Ordinary Shares at 414. 5x. On forward P/E, MKS Inc. is actually cheaper at 27. 1x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — MCTA or ACMR or ICHR or CANG or MKSI?

Over the past 5 years, Charming Medical Limited Class A Ordinary Shares (MCTA) delivered a total return of +319.

3%, compared to -3. 3% for Cango Inc. (CANG). Over 10 years, the gap is even starker: ACMR returned +32. 7% versus CANG's -44. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — MCTA or ACMR or ICHR or CANG or MKSI?

By beta (market sensitivity over 5 years), Cango Inc.

(CANG) is the lower-risk stock at 2. 49β versus Ichor Holdings, Ltd. 's 3. 78β — meaning ICHR is approximately 52% more volatile than CANG relative to the S&P 500. On balance sheet safety, Cango Inc. (CANG) carries a lower debt/equity ratio of 4% versus 24% for Charming Medical Limited Class A Ordinary Shares — giving it more financial flexibility in a downturn.

05

Which is growing faster — MCTA or ACMR or ICHR or CANG or MKSI?

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus -52. 7% for Cango Inc. (CANG). On earnings-per-share growth, the picture is similar: Cango Inc. grew EPS 960. 0% year-over-year, compared to -140. 6% for Ichor Holdings, Ltd.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — MCTA or ACMR or ICHR or CANG or MKSI?

Cango Inc.

(CANG) is the more profitable company, earning 37. 3% net margin versus -5. 6% for Ichor Holdings, Ltd. — meaning it keeps 37. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCTA leads at 22. 3% versus -4. 1% for ICHR. At the gross margin level — before operating expenses — MCTA leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is MCTA or ACMR or ICHR or CANG or MKSI more undervalued right now?

On forward earnings alone, MKS Inc.

(MKSI) trades at 27. 1x forward P/E versus 53. 2x for Ichor Holdings, Ltd. — 26. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CANG: 414. 9% to $3. 00.

08

Which pays a better dividend — MCTA or ACMR or ICHR or CANG or MKSI?

In this comparison, MKSI (0.

3% yield), ACMR (0. 2% yield) pay a dividend. MCTA, ICHR, CANG do not pay a meaningful dividend and should not be held primarily for income.

09

Is MCTA or ACMR or ICHR or CANG or MKSI better for a retirement portfolio?

For long-horizon retirement investors, MKS Inc.

(MKSI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+777. 0% 10Y return). Cango Inc. (CANG) carries a higher beta of 2. 49 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MKSI: +777. 0%, CANG: -44. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between MCTA and ACMR and ICHR and CANG and MKSI?

These companies operate in different sectors (MCTA (Healthcare) and ACMR (Technology) and ICHR (Technology) and CANG (Consumer Cyclical) and MKSI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MCTA is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; CANG is a small-cap deep-value stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

MCTA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 11%
Run This Screen
Stocks Like

ACMR

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 17%
  • Net Margin > 5%
Run This Screen
Stocks Like

ICHR

Quality Business

  • Sector: Technology
  • Market Cap > $100B
Run This Screen
Stocks Like

CANG

High-Growth Disruptor

  • Sector: Consumer Cyclical
  • Market Cap > $100B
  • Revenue Growth > 2916%
Run This Screen
Stocks Like

MKSI

High-Growth Disruptor

  • Sector: Technology
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform MCTA and ACMR and ICHR and CANG and MKSI on the metrics below

Revenue Growth>
%
(MCTA: 3.4% · ACMR: 34.2%)
Net Margin>
%
(MCTA: 19.3% · ACMR: 9.5%)
P/E Ratio<
x
(MCTA: 414.5x · ACMR: 46.0x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.